Advances in concurrent chemoradiotherapy plus immunotherapy forunresectable locally advanced non-small cell lung cancer
10.13491/j.issn.1004-714X.2025.03.025
- VernacularTitle:同步放化疗联合免疫疗法治疗不可手术局晚期NSCLC研究进展
- Author:
Lin DUAN
1
;
Jiaxin DAI
2
;
Yulong LIU
3
Author Information
1. Department of Oncology, People's Hospital of Manzhouli, Manzhouli 021400, China.
2. Occupational MedicineDepartment of Nuclear Industry Hospital 417, Xi'an 710600, China.
3. Clinical Cancer Diagnosis and Treatment Center, Second Affiliated Hospital of Soochow University, Suzhou 215004, China.
- Publication Type:ReviewArticles
- Keywords:
Locally advanced;
Non-small cell lung cancer;
Immune checkpoint inhibitor;
Concurrent chemoradiotherapy
- From:
Chinese Journal of Radiological Health
2025;34(3):456-462
- CountryChina
- Language:Chinese
-
Abstract:
Locally advanced non-small cell lung cancer (NSCLC) is a highly heterogeneous disease. For patients with driver gene-negative, unresectable NSCLC, traditional treatment primarily involves concurrent chemoradiotherapy. With the advent of the immunotherapy era, integrated treatment strategies combining concurrent chemoradiotherapy with immunotherapy have significantly improved therapeutic outcomes and substantially extended survival periods. This article summarizes the interaction mechanisms and clinical research progress of radiotherapy, chemotherapy, and immune checkpoint inhibitors in the treatment of NSCLC. This review also provides perspectives on the development of therapies in the future and predictive biomarkers, serving as a reference for treatment options for patients with unresectable locally advanced NSCLC.
